Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study

What Was Tested

Researchers studied Liraglutide in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

In the crossover set-up each of the participants took both Liraglutide and the comparison in turn, acting as their own control.

Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Blood Pressure Monitoring, Ambulatory, Coronary Artery Disease, Diabetes Mellitus, Type 2, Heart Rate, Hypoglycemic Agents and Liraglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in people with low blood pressure and orthostatic hypotension.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Journal of hypertension), a journal based in Netherlands.

More context: the Liraglutide compound page, Low blood pressure and orthostatic hypotension research.